Physician profile
James Thomas Chapman
NPI 1861058927
$622.51
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.75 · 2020: $120 · 2021: $314 · 2022: $143.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $82.15 | 2021 | |
| Novo Nordisk INC | $71.97 | 2020-2022 | |
| Abbott Laboratories | $62.48 | 2021-2022 | |
| Lilly USA, LLC | $58.35 | 2020-2021 | |
| Amgen INC. | $58.28 | 2020-2022 | |
| Pfizer INC. | $46.71 | 2021-2022 | |
| Dexcom, INC. | $29.66 | 2021 | |
| Abbvie INC. | $16.71 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.41 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.44 | 2021 | |
| Janssen Scientific Affairs, LLC | $15.35 | 2020 | |
| Ibsa Pharma INC. | $14.51 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.98 | 2019 | |
| Gilead Sciences, INC. | $12.97 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.